According to recent reports in the diabetes news, Roche Holding AG are developing a new a groundbreaking new diabetes drug . Currently in clinical trials, experimental diabetes drug taspoglutide has been shown to improve blood sugar control.
Roche are developing the drug in collaboration with Ipsen SA, and the companies say that the once-a-week diabetes medication also causes weight loss . The drug is part of a new class of diabetic medication.
The head of strategic marketing for metabolic diseases at Roche, Luke Miels, was reported as commenting: “It has the potential to have very strong effects on blood glucose and weight loss in an easy, simple device.”
Taspoglutide is human-sourced, and will seek to compete with the only GLP-1 on the market, Byetta .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…